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ABSTRACT  
Background: The main problem in ADHD patients is disinhibition, while ADD patients mostly suffer from slow cognitive speed. Although studies 
have shown that children with ADHD have deficits in executive function and working memory, and that acute use of Methylphenidate improves 
these functions, less study has been done on ADD patients. 
 
Methods: A four weeks, experimental, clinical trial was conducted with MPH 1 mg/kg/dose. Participants were 20 children aged 6-11 years with 
diagnosis ADD. Neuropsychological performance was assessed with scales taken from the Cambridge Neuropsychological Test Automated Battery. 
 
Results: Methylphenidate improved problems in some aspects of Stocking of Cambridge test including minimum moves, mean subsequent thinking 
time and in mean moves, between errors, strategy and total error aspects of Spatial Working Memory. It had no effect on Spatial Span and 
Intra/Extra Dimensional subscales. 
 
Conclusions: Studies show that ADHD patients have defect on all executive and working memory tests. Chronic use of Methylphenidate does not 
improve their performance. This different effect of chronic Methylphenidate on ADD and ADHD patients is another sign of different brain 
involvements in these two subgroups.   
 





Attention-deficit hyperactivity disorder (ADHD) is divided into two 
subtypes, the ADHD-combined, which includes inattention and 
hyperactivity/impulsive signs, and ADD (Attention Deficit Disorder). 
Patients with ADHD are hyperactive and restless. They move their 
hands and feet frequently and speak frequently. They are also 
impulsive, cannot wait for their turn to answer questions, and 
constantly interrupt others. On the other hand, ADD patients cannot 
pay attention to details. They have difficulty in completing and 
organizing a process. These patients get distracted by external 
stimuli, cannot concentrate, and therefore do not involve in thinking 
processes (1). Several studies have examined to what extent ADHD 
and ADD patients are different on various cognitive and executive 
measures (2, 3). Although both groups have attention problems, they 
have different inattention symptoms.  
 
ADHD patients mostly have inhibition problems and cannot stay 
focused. But, ADD patients have vigilance and processing speed 
problems. Day-dreaming, confusion, and staring problems have seen 
in ADD patients (4). ADD patients show less social initiative and are 
shy. On the other hand, ADHD patients have difficulty in self-
regulation. Despite these differences, both groups have reading and 




Different clinical findings and executive measures in these two 
groups indicate that ADD is not a sub-group of ADHD. Studies of 
patients with ADHD indicate that most of them suffer from a variety 
of cognitive impairments that extend beyond symptoms listed in the 
DSM-IV diagnostic criteria for ADHD. These include chronic 
problems in regulating alertness, reading comprehension, and 
modulating emotion and executive function (EF) (6). 
 
EF is the processes of problem solving, obtaining information about 
possible choices, and coordinating cognitive functions to make the 
best action for a given situation (7). These actions are often directed 
toward achieving long-term goals (8). Frontostriatal region is 
involved  in EF (9). Loss of frontostriatal dopamine and 
noradrenaline causes executive dysfunction in ADHD patients (10).  
 
Working memory is the brain’s ability to hold and manipulate 
information currently being processed and is tied up with short-
term memory. It is clear that many attention impairments associated 
with ADD and ADHD patients are because of chronic ineffectiveness 
of working memory and EF. Several cognitive functions, which 
extend beyond working memory, are apparently impaired in 
persons with ADD and ADHD (6). 
 
Different  studies  have  identified  that  children  with  ADHD  have 
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several deficits in sub-scales and in concerning in executing 
functions for the Cambridge Neuropsychological Test Automated 
Battery (CANTAB) (2, 11). These patients have problems in 
inhibition, working memory (12), attention set shifting (12, 13), and 
planning (14). 
 
Several authors proposed that different patterns of EF weaknesses 
could provide key evidence of discriminant validity between the 
DSM-IV inattentive and combined groups, particularly on measures 
of response inhibition (15, 16). 
 
Stimulant therapy by Methylphenidate (MPH) is the most commonly 
proven medication for ADHD. MPH can not only change behavior, 
activity, and efficacy of the attempts, and the ability to inhibit, but 
also can improve cognitive function (17). ADHD patients have 
hypoperfusion in the frontostriatal region. MPH can improve 
perfusion in these regions, induce inhibition and arousal, and 
consequently reduce impulsivity (18, 19). In addition, functional 
neuroimaging suggests that MPH modulates brain activity by 
increasing frontal and decreasing striatal activation in neurologically 
normal adults and children. Therefore, MPH can potentially increase 
both frontal and striatal metabolism in children with ADHD (17) and 
improve cognitive function in children with ADHD (10). Table 1 
shows studies that have been conducted on the acute and chronic 
effect of MPH on EF (20, 21). 
 
Studies in (22-25) show that MPH can improve the clinical signs of 
ADHD patients. In addition, studies in (26-29) show that MPH has 
 
Table 1: Results of previous researches on the acute and chronic effects of MPH on Executive Functioni 
Negative effect on tests Positive effect on tests Use method Author/date 
SOC SWM Acute Bedard et al.2004  
 SWM, Attention set shifting task Acute Mehta et al.2004 
 SWM, SSP, set shifting Acute Turner et al.2005 
 SWM Acute Mehta et al.2000 
 IED, SWM Acute Hoare et al.2007 
 SWM, IED, SSP Acute Kempton et al.1999 
SWM, SOC,IED  Acute Rhodes et al.2006 
SWM  Acute Rhodes et al.2004 
SSP, SWM  Chronic Coghill et al.2007 
SWM  Chronic Rhodes et al.2004 
 
patients. While the effects of chronic and acute using of MPH on the 
EF for ADHD patients have been studied in literature, these effects 
have not been fully explored for ADD patients. In this study, we 
assess the effect of the chronic use of MPH on the executive function 
of ADD patients.   
  
MATERIALS AND METHODS 
 
This study was approved by research ethics. All participants and 
parents/guardians completed written informed consent. 
 
Cambridge Neuropsychological Test Automated Battery 
(CANTAB) 
 
The best-available computerized test battery for evaluation of 
executive functions is Cambridge Automated Neuropsychological 
Test and Battery (CANTAB) (30). CANTAB has the following sub-
scales: Spatial Working Memory (SWM), Spatial Span (SSP), Stocking 
of Cambridge (SOC), Intra/Extra Dimensional Set Shifting (IED) 
evaluate executive function. 
 
Intra-Extra Dimensional Set Shift (IED) 
 
Intra-Extra Dimensional Set Shift is a test of rule acquisition and 
reversal. It evaluates visual discrimination, attentional set formation 
maintenance, and the flexibility of attention. This test is primarily 
sensitive to changes in the frontostriatal areas of the brain. Two 
figures are used in this test: color-filled shapes and white lines. 
Simple stimuli are made up of just one of these dimensions, whereas 
compound stimuli are made up of both. The participant starts by 
seeing two simple color-filled shapes, and must learn which one is 
correct by touching it. Feedback teaches the participant which 
stimulus is correct, and after six correct responses, the stimuli 
and/or rules are changed. These shifts are initially intra-dimensional 
(e.g. color filled shapes remain the only relevant dimension), and 
then become extra-dimensional (white lines become the only 
relevant dimension). Participants progress through the test by 
satisfying a set criterion of learning at each stage (6 consecutive 
correct responses). If at any stage, the participant fails to reach this 
criterion after 50 trials, the test terminates. This test has eighteen 
outcome measures, assessing errors, and numbers of trials and 
stages completed.ii 
  
Spatial Span (SSP)  
 
shown to the participant. Some of the squares briefly change color in 
a variable sequence. The participant must touch the boxes, which 
changed color, in the same order that they were displayed. The 
number of boxes increases from 2 at the start of the test to 9 at the 
final step. The sequence and color also vary through the test. This 
test has six outcome measures such as covering span length (the 
longest sequence successfully re-called), errors, number of attempts, 
and latency.iii 
 
Stockings of Cambridge (SOC)  
 
SOC is a spatial planning test to measure the frontal lobe function. 
The participant is shown two displays containing three colored balls. 
He/she must use the balls in the lower display to copy the pattern 
shown in the upper display. The balls can be moved one at a time by 
touching the required ball and then by touching the position to 
which it should be moved. The time taken to complete the pattern 
and the number of moves are considered as the measure of the 
participant’s planning ability. This test has three outcome measures, 
including the number and percentage of correct trials and latency 
(speed of participant’s response).iv 
 
Spatial Working Memory (SWM)  
 
SWM tests the ability to retain spatial information and to manipulate 
remembered items in the  working  memory. This  test  is a  sensitive  
executive dysfunction. The test begins with a number of colored 
squares (boxes) being shown on the screen. The participant should 
find a blue token among a number of boxes and use it to fill up an 
empty column on the right hand side of the screen. The number of 
boxes is gradually increasing, until it is necessary to reach a total of 
eight boxes. The color and position of the boxes are changing in 
different trials. The SWM test has twenty-four outcome measures. 
The main outcome measures include:  errors (touching boxes that 
have been found to be empty, and revisiting boxes which have 





Twenty children were recruited from consecutive outpatient 
referrals (aged from 6 to 11) to the Neurocognitive Center in Tehran. 
Exclusion criteria included history of neurological impairment, 
learning disability, mental retardation (IQ< 80), chronic physical 
illness, sensory or motor impairment, current or previous exposure 
to stimulant medication, abuse of any illegal drugs, the presence of 
commonly comorbid conditions, oppositional defiant disorder, 
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conduct disorder, and anxiety disorder. Eligible children had DSM-IV 
criteria for ADD and were interviewed by an experienced adolescent 
psychiatrist. ADD rating scale, Conners' parent rating scale, and the 
demographic form were answered by their parents. Then, the IQ of 
the children was evaluated by the Raven test. The control group was  
20 healthy children, interviewed by the psychiatrist. The child 
behavior checklist (CBCL) form was also completed in order to rule 




CANTAB and Conners' tests were performed as pre-tests and then 
MPH 0.5 mg/kg was used by patients twice a day at 8:00 AM and 





All analyses were conducted using SPSS (SPSS Inc., Chicago, Illinois) 




Clinical response to MPH in Conners and ADHD rating scales 
 
After one month of using MPH, ADD children showed significant 
improvement in inattention (p: 0.03), hyperactivity (p: 0.02), and 
ADHD (p: 0.008) indexes of Conners' test. However, using Ritalin had 
no significant improvement in the patients (p: 0.4).  
 
In ADHD rating scale, the patients showed significant improvement 
in total score (p: 0.02) indexes and inattention (p: 0.02), but did not 
show significant improvement in hyperactivity index (p: 0.2) 
 
The Results of CANTAB Tests 
 
Stockings of Cambridge (SOC)  
 
Using MPH significant helped ADD patients to improve the following 
measures:  mean moves (3 moves) (0.03), mean sub-sequent 
thinking (3 moves (0.002) and 5 moves (0.01)), and problems solved 
in minimum moves (0.003). But, MPH could not help the patients to 
improve mean initial thinking time (2, 3, 4 and 5 moves), mean 
moves (2, 4 and 5 moves), and mean sub-sequent thinking time (2 
and 4 moves) (p>0.05) (See Table 3). 
 
 
Intra-Extra Dimensional Set Shift (IED)  
 
Chronic use of MPH helped the patients to perform better in the 
following measures: stage errors, completed stage trials, EDS errors, 
errors block 1 to 9, pre-ED errors, stages completed, total errors, 
total errors adjusted, total trials, and total trials adjusted (p: 0.05) 
(See Table 4). 
 
Intra-Extra Dimensional Set Shift (IED)  
 
Chronic use of MPH helped the patients to improve the following 
indexes: completed stage errors, completed stage trials, EDS errors, 
errors block 1 to 9, pre-ED errors, stages completed, total errors, 
total errors adjusted, total trials, and total trials adjusted (p: 0.05) 
(See Table 4). 
 
Spatial Span (SSP)  
 
The patients did not show significant improvement in the following 
measures: span length, total errors, and total usage errors (p: 0.05) 
(See Table 4). 
 
Spatial Working Memory (SWM)  
 
Significant improvement was observed for the following measures of 
SWM: between errors (0.003), between errors (6 boxes) (0.007), 
strategy (0.04), and total errors (0.003). But no tangible 
improvement is observed for between errors (4 and 8 boxes), 
double errors (4, 6 and 8 boxes), and within errors (4, 6 and 8 




The results of this study show that MPH can improve Conner’s and 
ADHD rating scale in ADD patients. Parents of the ADD patients 
confirmed that attention and concentration had been improved. The 
hyperarousal caused by MPH increased the concentration of the 
ADD patients and helped them to perform better in the exams.  
 
In general, ADD patients suffer from low arousal and willpower. 
Starting a new task has high arousal for them. They may perform 
well at first, but as soon as they get involved in the process, 
everything becomes boring and they lose their interest and 
consequently their concentration decreases. Therefore, they skip 
tasks to maintain constant arousal. Using stimulant therapy such as 
MPH can increase their focus and allow them to complete the tasks.  
                                      
Table 2: The effect of chronic use of MPH on Conner’s-RS and ADHD-RS 
 WEEK 0 WEEK 4 P 









Inattention index 67.45 (9.4) 62.55 (11.0) 0.03* 
Hyperactivity index 59.30 (9.4) 55.10 (7.7) 0.02* 
ADHD index 64.85 (8.9) 59.80 (9.4) 0.008* 
ADHD RS Inattention 86.20 (19.1) 79.30 (21.1) 0.02* 
Hyperactivity 76.35 (12.4) 69.40 (22.3) 0.21 
Total score  83.95 (16.6) 76.10 (21.2) 0.02* 
Table 3: Effect of chronic use of MPH on SOC test 

















Mean initial thinking time, 3 moves  7986.47 (19040) 2791.52 (4215.1) 1.53 0.14 
Mean initial thinking time, 4 moves  3993.92 (2345.6) 3089.87 (1567.1) 1.44 0.16 
Mean initial thinking time, 5 moves  3498.26 (2477.0) 2873.76 (2295.9) 0.92 0.36 
Mean moves, 2 moves  2.02 (0.11) 2.00 (0.00) 1.00 0.33 
Mean moves, 3 moves 3.60 (0.85) 3.12 (.27) 2.23 0.03* 
Mean moves, 4 moves  5.71 (1.2) 5.58 (1.1) 0.31 0.75 
Mean moves,  5 moves  7.92 (1.0) 7.58 (1.3) 0.84 0.40 
Mean subsequent thinking time, 2 moves 1453.84 (2851.6) 246.25 (568.8) 1.91 0.07 
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Mean subsequent thinking time, 3 moves  2782.77 (3326.5) 264.32 (498.1) 3.54 0.002* 
Mean subsequent thinking time, 4 moves  4460.05 (4416.4) 2515.37 (5416.3) 1.43 0.16 
Mean subsequent thinking time, 5 moves  3242.23 (3020.4) 1878.59 (1430.3) -3.42 0.01* 
Problems solved in minimum moves 6.50 (1.8) 8.00 (1.2) 2.77 0.003* 
 











IED Completed stage errors 15.10 (8.4) 17.15 (10.7) - 0.65 0.52 
Completed stage trials 77.00 (23.9) 83.10 (28.2) - 0.74 0.46 
EDS errors 11.05 (10.7) 7.85 (9.9) 1.22 0.23 
Errors, block  1 0.60 (0.82) 0.90 (1.5) - 0.78 0.44 
Errors, block 2 1.60 (0.82) 1.50 (0.82) 0.52 0.60 
Errors, block 3 1.95 (4.3) 3.50 (5.7) - 0.93 0.36 
Errors, block 4 0.25 (0.55) 0.35 (0.81) - 0.49 0.62 
Errors, block 5 2.00 (2.4) 2.05 (2.2) - 0.06 0.94 
Errors, block 6 0.60 (0.99) 0.70 (0.86) - 0.34 0.73 
Errors, block 7 1.60 (1.2) 1.70 (1.7) - 0.23 0.82 
Errors, block 8 11.05 (10.7) 7.85 (9.9) 1.22 0.23 
Errors, block 9 6.95 (9.1) 5.25 (7.0) 0.59 0.55 
Pre-ED errors 8.60 (5.3) 10.70 (6.9) - 1.30 0.20 
Stages completed 8.00 (1.6) 8.30 (1.6) - 0.57 0.57 
IED total errors  26.30 (10.8) 23.80 (11.9) 1.00 0.33 
Total errors adjusted 40.05 (36.6) 35.05 (38.4) 0.43 0.66 
Total trials 99.50 (22.1) 95.60 (24.0) 0.63 0.53 
Total trials adjusted 127.00 (65.9) 118.10 (68.5) 0.43 0.66 
SSP Span length 4.42 (1.1) 4.53 (1.0) - 0.41 0.68 
Total errors 12.10 (5.0) 11.45 (5.7)  0.35 0.72 
Total usage errors 1.90 (1.9) 2.00 (2.1) - 0.24 0.81 
 





















Between errors (4 boxes) 3.00 (2.5) 2.10 (2.5) 1.70 0.10 
Between errors (6 boxes) 19.75 (8.4) 14.05 (8.8) 3.00 0.007* 
Between errors (8 boxes) 34.10 (9.9) 29.70 (12.4) 1.78 0.09 
Double errors 1.60 (2.2) 1.65 (2.8) - 0.06 0.95 
Double errors (4 boxes) 0.00 (0.00) 0.05 (0.2) - 1.00 0.33 
Double errors (6 boxes) 0.75 (1.8) 0.55 (1.6) 0.34 0.73 
Double errors (8 boxes) 0.85 (1.2) 1.05 (1.8) - 0.45 0.65 
Strategy 39.00 (4.2) 37.15 (6.0) 2.13 0.04* 
Total errors 57.90 (17.8) 46.70 (21.9) 3.40 0.003* 
Within errors 2.65 (3.4) 2.50 (3.6) 0.14 0.88 
Within errors (4 boxes) 0.05 (0.22) 0.15 (0.4) - 0.80 0.42 
Within errors (6 boxes) 1.35 (3.2) 0.55 (1.6) - 1.02 0.34 
Within errors (8 boxes) 1.25 (1.6) 1.80 (2.7) 0.96 0.31 
 
Note that, short time tests are not appropriate to study the behavior 
of ADD patients because the patients do not have executive 
dysfunction in short time processes. But, when it comes to long time 
processes, they have difficulties. If high arousal is produced in their 
brain, they can concentrate. That is why they seem to have executive 
dysfunction in clinic, but when short time tests are taken, they 
perform well.   
 
ADHD patients like ADD patients have low arousal state and are 
hyperactive.  When they use stimulants like MPH, their brain can 
maintain constant arousal. Thus, the disinhibition and hyperactivity 
decrease and their concentration increases (31). 
 
Chronic use of MPH can improve the performance of ADD patients in 
IED and SSP and can improve their scores in the SOC and SWM tests. 
It can also improve planning ability and reaction time of the SOC 
test, even though ADD patients have problems in time related 
measures of the SOC test. ADD patients do not have problem in the 
SWM test, but MPH can still improve their performance in this test. 
 
In addition, chronic use of MPH can improve the mean moves in the 
SOC test (3 moves), mean sub-sequent thinking (3 and 5 moves), and 
problems solved in minimum moves. MPH can also help the patients 
to improve the following indexes: between errors, between errors (6 
boxes), strategy, and total errors in the SWM test. These tests 
evaluate the ability of the patients in using spatial information in 
working memory.  
 
The results of this study show that MPH has no tangible effect on IED 
and SSP for ADD patients. Thus, flexibility of attention and spatial 
information are the psychological functions that may not be changed 
by the chronic prescription of MPH. 
 
Studies on healthy individuals show that acute use of MPH and 
stimulants can improve their working memory (SWM) and planning 
(SOC), but has no effect on the IED and fluency tests. When MPH is 
used for the second time on healthy individuals, it may decrease 
response latency and worsen their performance. A possible 
explanation is that MPH induces arousal in healthy individuals for
the first attempt, but when it is used again, it may cause 
hyperarousal (32-36). Previous studies claim that ADHD patients 
have problem in the tests related to executive function (SOC, IED, 
SSP, SWM) (12-14, 37). 
Mohammadi al. 
Asian J Pharm Clin Res, Vol 8, Issue4, 2015,330-335  
333 
 
Chronic use of MPH has no effect in the SOC, IED, SSP, and SWM 
tests for ADHD patients (14, 38), but acute use of MPH can improve 
their performance on SWM, IED, and SOC (12, 39). However, some 
studies claim that acute use of MPH does not have any effect on the 
IED, SOC, and SWM tests (10, 14).  
 
MPH has a short half-life. Its acute use can raise arousal and 
improve inhibition in ADHD patients. The chronic use of MPH does 
not show the same results. This may be related to the tolerance 
developed in the patients (12, 39). If disinhibition is controlled in 
ADHD patients, they can executive function and use their working 
memory. If the impulsive behavior of these patients is controlled, 
they can also answer the tests correctly.  
 
When MPH is used chronically and after its half-life ends, it cannot 
raise arousal to the initial level for the ADHD patients, So, the 
patients still have problems in completing the tests (14, 38). But, 
the results of this study show that the chronic use of MPH can have 
positive effects for the ADD patients.  
 
ADHD patients have defects on frontostriatal areas of their brain 
and have difficulty in inhibition of attempts, specially for 
movement (3). On the other hand, ADD patients have problem in 
prefrontal areas of their brain (40). ADD patients do not have a 
disinhibition problem, but they are sluggish and therefore they 
show different reactions to MPH. The chronic and acute use of MPH 
can improve the sluggish problem of the ADD patients, by 




More investigation should be conducted on the acute and chronic 
use of MPH in ADD and ADHD patients. Previous studies show that 
the acute use of MPH can enhance inhibition and reduce 
impulsivity of the ADHD patients. But, the chronic use of MPH does 
not show these improvements. To our best of knowledge, no study 
has been done on the acute use of MPH for ADD patients. In this 
paper, we showed that the chronic use of MPH did not worsen the 
performance of the ADD patients and could even improve their 
performance in planning, working memory, and reaction time. Our 
findings approved the theory that ADHD and ADD patients have 
different brain involvement and therefore have different treatment 
outcomes. The results of this study get rise to new research 
questions. For instance, how do ADD patients perform in other 
cognitive exams after the use of MPH? Addressing this question 
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